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Abstract We found a potent hyperglycemic effect of proadre-
nomedullin N-terminal 20 peptide (PAMP) after intra-third
cerebroventricular administration at a dose of 10 nmol in fasted
mice. PAMP has four homologous residues with bombesin (BN),
a hyperglycemic peptide. PAMP showed affinity for gastrin-
releasing peptide preferring receptor (GRP-R) and neuromedin B
preferring receptor. The PAMP-induced hyperglycemic effect
was inhibited by [D-Phe6, Leu-NHEt13, des-Met14]-BN (6^14),
GRP-R specific antagonist, indicating that the hyperglycemic
effect is mediated at least in part via GRP-R. Furthermore,
pretreatment of K-adrenergic blocker inhibited the PAMP-
induced hyperglycemia and hyperglucagonemia, suggesting that
the increase of glucagon secretion through K-adrenergic activa-
tion is involved in this hyperglycemic effect of PAMP.
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1. Introduction
Proadrenomedullin N-terminal 20 peptide (PAMP) is a bio-
active peptide which is derived from a precursor of potent
hypotensive peptide adrenomedullin (AM) originally isolated
from the human pheochromocytoma [1]. The AM gene is
transcribed and the gene product translates within not only
peripheral organs such as the adrenal gland and vasoculature
but also in the central nervous system [2]. AM is a novel
member of the calcitonin gene-related peptide (CGRP) super-
family, and has a⁄nity for CGRP receptor and AM receptor.
AM has been shown to mediate, at least in part, the vaso-
dilator e¡ect through the CGRP receptor. Peripherally admin-
istered PAMP transiently lowers blood pressure, although its
e¡ect is less potent than AM [3]. Except for its hypotensive
e¡ect, the biological function of PAMP presently remains un-
clear. It was reported using a radioligand of PAMP that spe-
ci¢c binding sites for PAMP are widely distributed in plasma
and tissues such as the brain, lung and kidney, and relatively
abundant binding sites are present in the adrenal glands and
aorta [4]. Despite much e¡ort, however, the PAMP receptor
has not been cloned.
We found that centrally administered PAMP potently and
rapidly elevates blood glucose levels in fasted mice. In a pre-
vious study, we reported that bioactive peptides derived from
food protein, with only three or four homologous residues
with the endogenous bioactive peptides, have a⁄nity for their
receptors [5^7]. We noticed that PAMP (ARLDVA-
SEFRKKWNKWALSR-NH2) has four homologous residues
with bombesin (BN) (Pyr-QRLGNQWAVGHLM-NH2),
which exerts hyperglycemia after central administration [8,9].
BN is an amidated tetradecapeptide ¢rst isolated from am-
phibian skin [10]. BN-like peptides (gastrin-releasing peptide
[11], neuromedin B [12] and neuromedin C [13]) have also
been demonstrated to exist throughout the mammalian gas-
trointestinal and nervous system. The three known mamma-
lian BN receptor subtypes are the gastrin-releasing peptide
preferring receptor (GRP-R) [14], neuromedin B preferring
receptor (NMB-R) [15] and BN receptor subtype 3 (BRS-3)
[16]. Exogenous administration of these BN-like peptides into
various organ systems elicits a wide range of responses includ-
ing secretion of gastrointestinal hormones and gastric acid,
and regulation of smooth muscle [17]. These peptides are
postulated to play roles in thermoregulation, metabolism, be-
havior and satiety.
In the present study, we investigated whether PAMP has
a⁄nity for the BN receptor. [D-Phe6, Leu-NHEt13, des-Met14]-
BN (6^14) [18,19] was used to examine whether the hyper-
glycemic e¡ect is mediated via GRP-R receptor. Furthermore,
we evaluated the involvement of the sympathetic nervous sys-
tem in the action of PAMP, using phentolamine (K-adrenergic
blocker).
2. Materials and methods
2.1. Materials
Human PAMP, PAMP-related peptide and [D-Phe6, LAla11, Phe13,
Nle14]-BN (6^14) were synthesized by Fmoc strategy using a PS3
peptide synthesizer (Protein Technologies, USA). The peptides were
puri¢ed by reverse-phase high performance liquid chromatography on
an octadecyl silica column. BN, neuromedin B and neuromedin C
were purchased from the Peptide Institute Inc. (Osaka, Japan). 125I-
[Tyr4]-BN was obtained from NEN (Boston, MA, USA). BALB 3T3
cells stably transfected with NMB-R, GRP-R, BRS-3 were a gift from
Mitsubishi-Tokyo Pharmaceuticals Inc. (Tokyo, Japan). Dulbecco’s
modi¢ed Eagle medium (DMEM) and G418 sulfate (geneticin) were
obtained from Gibco BRL (Grand Island, NY, USA). The 0.05%
trypsin^EDTA solution, soybean trypsin inhibitor, benzamidine, bo-
vine serum albumin and phentolamine were from Sigma Chemical (St.
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Louis, MO, USA). Bacitracin was purchased from Wako (Osaka,
Japan). GRP-R antagonist, [D-Phe6, Leu-NHEt13, des-Met14]-BN
(6^14) was obtained from Bachem (Bubendorf, Switzerland).
2.2. Animals
Male ddY mice (SLC, Shizuoka, Japan) at 7 weeks of age served as
the experimental animals. Each mouse was individually housed in
regulated conditions (22‡C on a 12 h light^dark cycle). Food and
water were available ad libitum, except as otherwise indicated.
Intra-third cerebroventricular (i.c.v.) injection was performed as
described previously [20]. Mice were anesthetized with sodium pento-
barbital (80^85 mg/kg intraperitoneal (i.p.)) and placed in a stereo-
taxic instrument. A hole was made through the skull using a needle
aimed 0.9 mm lateral to the suture and 0.9 mm posterior to the
bregma. A 24-gauge cannula beveled at one end over a 3 mm distance
(Safelet-Cas, Nipro, Osaka, Japan) was implanted into the third cer-
ebral ventricle. Animals were tested 1 week or more after implanta-
tion.
2.3. E¡ect of PAMP on blood glucose
Mice were deprived of food for 18 h with free access to water.
Blood samples were obtained from the orbital sinus under ether anes-
thesia at 15, 30 and 60 min after i.c.v. injection of PAMP in 4 Wl of
arti¢cial cerebrospinal £uid (ACSF) or ACSF alone. Plasma was sep-
arated from the blood and stored at 320‡C until analysis. All experi-
ments were approved by our University animal committee.
2.4. BN antagonist and K-adrenergic blocker studies
To establish whether the e¡ect of central administered PAMP was
via GRP-R, the blood glucose was measured at 15 min after i.c.v.
injection of 10 nmol PAMP and [D-Phe6, Leu-NHEt13, des-Met14]-BN
(6^14), BN antagonist. To understand the underlying mechanism for
the rapid hyperglycemic response to PAMP, 10 mg/kg phentolamine
or saline was peripherally injected 30 min before i.c.v. injection of
PAMP or ACSF. The blood glucose and plasma glucagon levels
were determined 15 min after i.c.v. administration.
2.5. Biochemical analyses
Blood glucose was determined by the glucose oxidase method. NE-
FAs, triglycerides and cholesterols were measured with an enzymatic
colorimetric assay (Wako, Osaka, Japan). Insulin levels were deter-
mined using an enzyme-linked immunosorbent assay insulin kit (Mor-
inaga, Tokyo, Japan). Glucagon and corticosterone levels were as-
sayed by RIA.
2.6. Growth and maintenance of cells
BALB 3T3 cells stably transfected with NMB-R, GRP-R and BRS-
3 were grown in DMEM containing 25 mM HEPES. All cell media
were supplemented with 10% (v/v) fetal bovine serum (JRH bioscien-
ces), 25 IU/ml penicillin (Banyu Pharmaceutical Co., Ltd., Tokyo,
Japan), 25 Wg/ml streptomycin (Meiji Seika Kaisha, Ltd., Tokyo, Ja-
pan), 1.25 Wg/ml amphotericin (ICN Pharmaceuticals, Inc., Costa
Mesa, CA, USA) and 400 Wg/ml geneticin. All cells were maintained
at 37‡C in a 5% CO2 atmosphere. Cells were subcultured every 3^4
days at con£uence after detaching the cells with trypsin^EDTA solu-
tion.
2.7. Preparation of membrane from cells
The homogenizing bu¡er [21] contained 50 mM Tris^HCl (pH 7.4),
0.2 mg/ml soybean trypsin inhibitor, 0.2 mg/ml benzamidine and 0.1%
bacitracin. Then 1U107 cells/ml were homogenized at 4‡C with Bio-
mixer (Nihonseiki Kaisha Ltd.) for 30 s. The homogenized suspension
was centrifuged at 1500 rpm for 10 min at 4‡C. The supernatant was
removed and recentrifuged at 20 000 rpm for 20 min. The pellet was
resuspended in homogenizing bu¡er and stored at 380‡C.
2.8. BN receptor assay
The radioreceptor assay was performed according to the method of
Moody et al. [22]. Brie£y, 50 pM 125I-[Tyr4]-BN was incubated with
the membrane from rat brain or cells stably transfected with NMB-R,
GRP-R and BRS-3 at 4‡C for 24 min in 50 mM Tris^HCl bu¡er
containing 2 Wg/ml bacitracin and 0.1% bovine serum albumin (w/v)
(pH 7.4). Membrane bound 125I-[Tyr4]-BN was separated by ¢ltration
through a GF/B ¢lter (Whatman, Maidstone, UK). The ¢lter was
washed promptly with ice cold 50 mM Tris^HCl bu¡er containing
0.1% bovine serum albumin and assayed for radioactivity in a gamma
counter. Speci¢c binding was obtained by subtracting non-speci¢c
binding in the presence of an excess (100 WM) unlabeled BN from
total binding.
2.9. Statistical analysis
Values are expressed as the mean þ S.E.M. Individual group means
were compared by either unpaired Student’s t test for two-group
comparisons or multiple Bonferroni comparison for more than two
groups. P values of less than 0.05 were considered to be statistically
signi¢cant.
3. Results
The e¡ects of i.c.v. administration of PAMP on blood glu-
cose are shown in Fig. 1. The initial experiment showed that
PAMP (10^30 nmol/mouse) potently increased blood glucose
levels at 30 min after central injection in a dose-dependent
manner (Fig. 1A). In the time course study, 10 nmol of
PAMP potently and rapidly increased blood glucose levels
at 15 min after i.c.v. injection, and the hyperglycemia lasted
for 1 h (Fig. 1B).
Due to the sequence homology of PAMP with BN, the
receptor a⁄nity of PAMP for the BN receptor was investi-
gated. In the rat brain membrane, 50% of speci¢c 125I-[Tyr4]-
BN binding (IC50) was inhibited when the BN concentration
was 5.0U1039 M. PAMP had a⁄nity for the BN receptor
(IC50 = 5.2U1038 M) (Table 1), although it was one tenth
lower than that of BN. The a⁄nities of PAMP(1^20)-OH
and PAMP(9^20)-NH2 for BN receptor were lower
(IC50 = 2.2U1037 M) than PAMP. The relative potency of
the BN receptor a⁄nity was PAMPsPAMP(1^20)-OH =
PAMP(9^20)-NH2sPAMP(12^20)-NH2sPAMP(13^20)-N-
Table 1
The a⁄nities of PAMP, PAMP-related peptides and BN-related peptides for BN receptor in rat brain membrane or cells stably transfected
with NMB-R, GRP-R and BRS-3 (IC50 ; M)
Peptide Brain membrane Cells stably transfected with BN receptor
rNMB-R mGRP-R hBRS-3 mBRS-3
PAMP 5.2U1038 1.8U1038 2.2U1038 6.8U1038 6.8U1038
BN 5.0U1039 1.4U1038 3.3U1039 3.3U1039 3.3U1039
Neuromedin C 5.4U1039 4.0U1038 5.0U1039 7.8U1039 5.3U1039
Neuromedin B 2.4U1038 1.3U1039 2.6U1038 4.7U1038 4.3U1038
[D-Phe, LAla11, Phe13, Nle14]-BN (6^14) 1.0U1039 1.5U1038 1.3U1039 1.4U1039 1.4U1039
PAMP(1^20)-OH 2.2U1037
PAMP(9^20)-NH2 2.2U1037
PAMP(12^20)-NH2 9.1U1037
PAMP(13^20)-NH2 1.7U1036
PAMP(13^20)-OH 1.6U1035
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H2sPAMP(13^20)-OH. From these ¢ndings, it was indicated
that the amide group and the amino acid sequence at the C-
terminal of PAMP were necessary to bind the BN receptor.
To compare the a⁄nities of PAMP for each BN receptor
subtype, BALB 3T3 cells stably transfected with NMB-R,
GRP-R and BRS-3 were used. PAMP had high a⁄nities for
NMB-R and GRP-R; the IC50 values were 1.8U1038 and
2.2U1038 M, respectively (Table 1). The a⁄nity of PAMP
for BRS-3 was less potent than NMB-R and GRP-R
(IC50 = 6.8U1038 M).
To investigate whether PAMP elevates blood glucose via
the BN receptor, we coadministered PAMP and GRP-R an-
tagonist, [D-Phe6, Leu-NHEt13, des-Met14]-BN (6^14). The in-
crease of blood glucose after central administration of 10
nmol of PAMP was 63% inhibited by 10 nmol of GRP-R
antagonist (Fig. 1C). The dose of the GRP-R antagonist
was limited to the solubility of that in ACSF.
Table 2 shows the e¡ect of PAMP on plasma insulin,
NEFA, triglyceride and cholesterol levels. There was no dif-
ference in the insulin levels at 15 min after i.c.v. injection. The
plasma insulin levels were signi¢cantly increased at 60 min
after i.c.v. administration of PAMP, following the hypergly-
cemic action of PAMP. The NEFA levels at 30 min after
PAMP administration were slightly higher than ACSF. There
was no di¡erence in the concentrations of plasma triglycerides
and cholesterol after injection of PAMP in the present study.
The e¡ects of phentolamine, K-adrenergic blocker, on
PAMP-induced hyperglycemia are shown in Fig. 2A. First,
10 mg/kg phentolamine or saline was peripherally injected
30 min before i.c.v. administration of PAMP or ACSF. The
i.p. administered phentolamine lowered the basal blood glu-
cose levels in mice injected with ACSF. The phentolamine
pretreatment inhibited the PAMP-induced hyperglycemia by
50% at 15 min after i.c.v. injection, with the e¡ect being highly
signi¢cant. Glucagon levels were signi¢cantly elevated at 15
min post i.c.v. administration of PAMP, and the pretreatment
Table 2
E¡ect of i.c.v. injection of PAMP (10 nmol/mouse) on plasma insulin, NEFA, triglyceride and cholesterol concentrations in fasted mice
Time after injection 15 min 30 min 60 min
Group ACSF PAMP ACSF PAMP ACSF PAMP
Insulin (pM) 63.5 þ 28.6 50.1 þ 22.9 68.7 þ 13.5 120.9 þ 29.6 58.9 þ 9.8 109.3 þ 21.7*
NEFA (g/l) 0.15 þ 0.01 0.15 þ 0.01 0.24 þ 0.01 0.27 þ 0.01* 0.13 þ 0.01 0.15 þ 0.01
Triglyceride (g/l) 0.61 þ 0.12 0.53 þ 0.07 0.66 þ 0.04 0.55 þ 0.08 0.62 þ 0.10 0.45 þ 0.05
Cholesterol (mM) 3.86 þ 0.52 3.79 þ 0.33 3.49 þ 0.14 3.73 þ 0.26 3.11 þ 0.34 3.13 þ 0.28
Values are expressed as mean þ S.E.M. of 6^7 mice.
*P6 0.05 compared with the ACSF-treated group by Student’s t test.
Fig. 1. E¡ect of i.c.v. administration of PAMP on blood glucose in fasted mice. Male ddY mice were injected with 4 Wl of 3, 10 or 30 nmol
PAMP, and the blood glucose was measured 30 min after central administration (A). In the time course study (B), 10 nmol of PAMP was
i.c.v. administered. In GRP-R antagonist study (C), 10 nmol PAMP and 1 or 10 nmol [D-Phe6, Leu-NHEt13, des-Met14]-BN (6^14) were i.c.v.
coadministered, and the blood glucose was measured 15 min after administration. Each column represents the mean þ S.E.M. of 5^7 mice.
*P6 0.05, **P6 0.01 compared with the ACSF-treated group using the unpaired Student’s t test in A and B, and compared with each group
by Bonferroni’s t test in C.
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of K-blocker e¡ectively abolished the hyperglucagonemic re-
sponse (Fig. 2B). There was no di¡erence in plasma cortico-
sterone levels between the control and ACSF-treated animals
at 15 min after i.c.v. administration (Fig. 2C).
4. Discussion
We have shown, for the ¢rst time, that centrally adminis-
tered PAMP potently and rapidly increases blood glucose in
fasted conscious mice in a dose-dependent manner. The ¢nd-
ings of the binding assay indicated that PAMP had high af-
¢nity for GRP-R and NMB-R. The PAMP-induced hyper-
glycemic e¡ect was signi¢cantly reversed by GRP-R
antagonist, [D-Phe6, Leu-NHEt13, des-Met14]-BN (6^14), sug-
gesting that the hyperglycemic e¡ect was, at least in part,
mediated via GRP-R.
Centrally administered PAMP acutely exerted a marked
hyperglycemic action in conscious animals within 15 min.
There was no di¡erence in the plasma insulin levels between
ACSF- and PAMP-treated animals 15 min after administra-
tion, although the insulin levels increased thereafter. The sub-
sequent hyperinsulinemia appeared to be secondary to the
acute hyperglycemia.
To understand the underlying mechanism for the rapid hy-
perglycemic response to centrally administered PAMP, the
e¡ects of peripherally pretreated K-adrenergic blocker (phen-
tolamine) on PAMP-induced hyperglycemia and plasma glu-
cagon levels were investigated in mice. The i.p. pretreatment
of K-adrenergic blocker inhibited the hyperglycemic response
to i.c.v. PAMP by 50%. It is well-known that increased glu-
cagon secretion, in concert with adrenergic mechanisms, is a
primary counter-regulatory response for the recovery of glu-
cose levels during hypoglycemia [23,24]. Central administra-
tion of PAMP stimulated the glucagon secretion and the
PAMP-induced hyperglucagonemia was inhibited by the pre-
treatment with K-blocker. Furthermore, peripheral pretreat-
ment with pentobarbital, which suppresses the activation of
the sympathetic nervous system [25], e¡ectively inhibited the
PAMP-induced hyperglycemic response in the preliminary ex-
periment (data not shown). On the other hand, there was no
di¡erence in plasma corticosterone levels between controls
and PAMP-treated mice. These ¢ndings suggest that PAMP-
induced hyperglycemia after i.c.v. administration is due, at
least in part, to the increased glucagon secretion, through K-
adrenergic activation in the sympathetic nervous system.
The plasma NEFA levels were assayed, because the release
of glucose and NEFA from their storage sites in the liver and
white adipose tissue, respectively, are controlled by separable
central systems with di¡erent peripheral mechanisms [26]. The
plasma NEFAs at 30 min post i.c.v. injection of PAMP were
slightly but signi¢cantly higher than ACSF. Glucagon secre-
tion may participate in the NEFA release after central admin-
istration of PAMP.
Both PAMP [27] and BN [28] exert hypertensive actions
when administered centrally in conscious rats. These e¡ects
are mediated via activation of the sympathetic K-adrenergic
nerve system. The hypertensive e¡ect of centrally injected
PAMP may thus be mediated via BN receptor. However, it
has been reported that peripheral administration of PAMP
decreases blood pressure in conscious rats [29] and BN in-
versely exhibits the hypertensive action [30]. This may suggest
the existence of a more speci¢c PAMP receptor. Further in-
vestigations may provide additional insight into the role of
PAMP in the cardiovascular system.
In conclusion, the present ¢ndings demonstrate that cen-
trally administered PAMP elevates blood glucose and
PAMP has a⁄nity for the BN receptor. The PAMP-induced
hyperglycemic e¡ect was inhibited by GRP-R antagonist, sug-
gesting that PAMP action is mediated, at least in part,
through GRP-R. Furthermore, the hyperglycemia involves
the increase of glucagon secretion through K-adrenergic acti-
vation.
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